Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy

Genes and Development

Volumn 28, Issue 10, 2014, Pages 1085-1100

  Yan, Kenneth ^a,b,c   Wu, Qiulian ^a   Yan, Diana H ^b   Lee, Christine H ^a,b   Rahim, Nasiha ^a   Tritschler, Isabel ^a,d   DeVecchio, Jennifer ^a   Kalady, Matthew F ^a   Hjelmeland, Anita B ^a   Rich, Jeremy N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

BMP antagonists; Bone morphogenetic proteins (BMPs); Cancer stem cells; Glioblastoma; Gremlin1; Stem cell hierarchies

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; GREMLIN1 PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN; PROTEIN P21; PROTEIN P53; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

BMP ANTAGONISTS; BONE MORPHOGENETIC PROTEINS (BMPS); CANCER STEM CELLS; GLIOBLASTOMA; GREMLIN1; STEM CELL HIERARCHIES;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HETEROGRAFTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84900796733     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.235515.113     Document Type: Article

References (78)

1. Abbas T, Dutta A. 2009. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414.
2. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al. 2000. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci 97: 12846-12851.
3. Ades L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, et al. 2010. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 115: 1690-1696.
4. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, et al. 2010. TGF-b receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18: 655-668.
5. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006a. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
6. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. 2006b. Stem celllike glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 7843-7848.
7. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. 2008. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 68: 6043-6048.
8. Beck SE, Jung BH, Del Rosario E, Gomez J, Carethers JM. 2007. BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ ERK. Cell Signal 19: 1465-1472.
9. Besson A, Dowdy SF, Roberts JM. 2008. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169.
10. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, et al. 2012. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22: 765-780.
11. Brubaker KD, Corey E, Brown LG, Vessella RL. 2004. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91: 151-160.
12. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
13. The Cancer Genome Atlas. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
14. Carvalho BS, Irizarry RA. 2010. A framework for oligonucleotide microarray preprocessing. Bioinformatics 26: 2363-2367.
15. Chen B, Athanasiou M, Gu Q, Blair DG. 2002. Drm/Gremlin transcriptionally activates p21(Cip1) via a novel mechanism and inhibits neoplastic transformation. Biochem Biophys Res Commun 295: 1135-1141.
16. Chen A, Wang D, Liu X, He S, Yu Z, Wang J. 2012a. Inhibitory effect of BMP-2 on the proliferation of breast cancer cells. Mol Med Rep 6: 615-620.
17. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. 2012b. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526.
18. Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich JN, Bao S. 2011a. Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 406: 643-648.
19. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich JN, Bao S. 2011b. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 30: 800-813.
20. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, et al. 2013. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153: 139-152.
21. Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM, Graf D, Mitsiadis T, Herold-Mende C, Besser D, et al. 2010. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 133: 1961-1972.
22. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhauser C, et al. 2013. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23: 238-248.
23. Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E, Aura C, Barba I, Peg V, Prat A, et al. 2012. USP15 stabilizes TGF-b receptor I and promotes oncogenesis through the activation of TGF-b signaling in glioblastoma. Nat Med 18: 429-435.
24. Eyler CE, Wu Q, Yan K, Macswords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, et al. 2011. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 146: 53-66.
25. Franzen A, Heldin NE. 2001. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun 285: 773-781.
26. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, et al. 2012. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-oncol 14: 215-221.
27. Gallo M, Ho J, Coutinho FJ, Vanner R, Lee L, Head R, Ling EK, Clarke ID, Dirks PB. 2013. A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res 73: 417-427.
28. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG. 2012. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150: 764-779.
29. Gargiulo G, Cesaroni M, Serresi M, de Vries N, Hulsman D, Bruggeman SW, Lancini C, van Lohuizen M. 2013. In vivo RNAi screen for BMI1 targets identifies TGF-b/BMP-ER stress pathways as key regulators of neural-and malignant glioma-stem cell homeostasis. Cancer Cell 23: 660-676.
30. Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, et al. 2011. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). J Neurooncol 104: 801-809.
31. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Belmonte JC, Choe S. 2002. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636-642.
32. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, Nakano I. 2013. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells 31: 870-881.
33. Hsu MY, Rovinsky SA, Lai CY, Qasem S, Liu X, How J, Engelhardt JF, Murphy GF. 2008. Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation. Lab Invest 88: 842-855.
34. Hu Y, Smyth GK. 2009. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347: 70-78.
35. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. 2009. Autocrine TGF-b signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5: 504-514.
36. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
37. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, et al. 2013. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 31: 1051-1063.
38. Khasraw M, Simeonovic M, Grommes C. 2012. Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther 12: 1101-1111.
39. Kim M, Yoon S, Lee S, Ha SA, Kim HK, Kim JW, Chung J. 2012. Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion. PLoS ONE 7: e35100.
40. Kishigami S, Mishina Y. 2005. BMP signaling and early embryonic patterning. Cytokine Growth Factor Rev 16: 265-278.
41. Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, et al. 2012. Laminin a2 enables glioblastoma stem cell growth. Ann Neurol 72: 766-778.
42. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, et al. 2008. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastomainitiating cells. Cancer Cell 13: 69-80.
43. Lesniak MS. 2006. Targeted therapy for malignant glioma: neural stem cells. Expert Rev Neurother 6: 1-3.
44. Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. 2009. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem 284: 16705-16709.
45. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. 2006. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
46. Liu C, Tian G, Tu Y, Fu J, Lan C, Wu N. 2009. Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas. Jpn J Clin Oncol 39: 625-631.
47. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R, Stassi G. 2011. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140: 297-309.
48. Marques-Torrejon MA, Porlan E, Banito A, Gomez-Ibarlucea E, Lopez-Contreras AJ, Fernandez-Capetillo O, Vidal A, Gil J, Torres J, Farinas I. 2013. Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression. Cell Stem Cell 12: 88-100.
49. Miyazaki H, Watabe T, Kitamura T, Miyazono K. 2004. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23: 9326-9335.
50. Mulvihill MS, Kwon YW, Lee S, Fang LT, Choi H, Ray R, Kang HC, Mao JH, Jablons D, Kim IJ. 2012. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PLoS ONE 7: e42264.
51. Namkoong H, Shin SM, Kim HK, Ha SA, Cho GW, Hur SY, Kim TE, Kim JW. 2006. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 6: 74.
52. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, Garcia-Dorado D, Poca MA, Sahuquillo J, Baselga J, et al. 2009. TGF-b increases glioma-initiating cell selfrenewal through the induction of LIF in human glioblastoma. Cancer Cell 15: 315-327.
53. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. 2006. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765.
54. Porlan E, Morante-Redolat JM, Marques-Torrejon MA, Andreu-Agullo C, Carneiro C, Gomez-Ibarlucea E, Soto A, Vidal A, Ferron SR, Farinas I. 2013. Transcriptional repression of Bmp2 by p21Waf1/Cip1 links quiescence to neural stem cell maintenance. Nat Neurosci 16: 1567-1575.
55. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
56. Rheinbay E, Suva ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, et al. 2013. An aberrant transcription factor network essential for wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 3: 1567-1579.
57. Rider CC, Mulloy B. 2010. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J 429: 1-12.
58. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, Barker N, Shroyer NF, van de Wetering M, Clevers H. 2011. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469: 415-418.
59. Secondini C, Wetterwald A, Schwaninger R, Thalmann GN, Cecchini MG. 2011. The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis. PLoS ONE 6: e16078.
60. Sieber C, Kopf J, Hiepen C, Knaus P. 2009. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 20: 343-355.
61. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature 432: 396-401.
62. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE, et al. 2006. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci 103: 14842-14847.
63. Tate CM, Pallini R, Ricci-Vitiani L, Dowless M, Shiyanova T, D'Alessandris GQ, Morgante L, Giannetti S, Larocca LM, di Martino S, et al. 2012. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ 19: 1644-1654.
64. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, McCarty JH. 2011. Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by b8 integrin. Cancer Res 71: 6371-6381.
65. Varga AC, Wrana JL. 2005. The disparate role of BMP in stem cell biology. Oncogene 24: 5713-5721.
66. Verheyden JM, Sun X. 2008. An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud outgrowth. Nature 454: 638-641.
67. Vigneron A, Cherier J, Barre B, Gamelin E, Coqueret O. 2006. The cell cycle inhibitor p21waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression. J Biol Chem 281: 34742-34750.
68. Walsh DW, Godson C, Brazil DP, Martin F. 2010. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 20: 244-256.
69. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. 2008. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE 3: e3769.
70. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, et al. 2009. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404.
71. Wang L, Park P, Zhang H, La Marca F, Claeson A, Valdivia J, Lin CY. 2011. BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther 11: 457-463.
72. Weller M, Cloughesy T, Perry JR, Wick W. 2013. Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro-oncol 15: 4-27.
73. Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L, Xiao HL, Wang B, Yi L, Wang QL, et al. 2012. Tumor-associated microglia/ macrophages enhance the invasion of glioma stem-like cells via TGF-b1 signaling pathway. J Immunol 189: 444-453.
74. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, Kurman RJ. 2011. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24: 1248-1253.
75. Yi L, Xiao H, Xu M, Ye X, Hu J, Li F, Li M, Luo C, Yu S, Bian X, et al. 2011. Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol 232: 75-82.
76. Zhang X, Wu J, Li X, Fu L, Gao D, Bai H, Liu X. 2002. [Effects of recombinant human bone morphogenic protein-2 and hyaluronic acid on invasion of brain glioma in vivo]. Zhonghua Yi Xue Za Zhi (Taipei) 82: 90-93.
77. Zhang MY, Wu J, Gong X, Chen RK, Fang JS. 2009. [Clinical significance of BMP-2 protein and mRNA expression in human glioma]. Xibao Yu Fenzi Mianyixue Zazhi 25: 637-639.
78. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al. 2008. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455: 1129-1133.